A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years

Back to Search
Print
Bookmark Trial

NCT01830855

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Study Location
Birmingham Pediatric Associates, PC
Birmingham, Alabama, 35205, United States
See other locations
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Meningococcal Vaccine
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
10-18 years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Male or female subject aged >=10 and <19 years at the time of enrollment.

2. Healthy subject as determined by medical history, physical examination, and judgment of the investigator.

3. Negative urine pregnancy test for all female subjects.

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


1. Previous vaccination with any meningococcal serogroup B vaccine.


2. Subjects who have received prior HAV vaccination.


3. Subjects who are scheduled to receive 1 or more doses of an HPV vaccine as part of a
3-dose series during the period between Visit 1 and 28 days after the second
vaccination.


4. Subjects receiving any allergen immunotherapy with a nonlicensed product or receiving
allergen immunotherapy with a licensed product and are not on stable maintenance
doses.


5. A known or suspected defect of the immune system that would prevent an immune response
to the vaccine, such as subjects with congenital or acquired defects in B cell
function, those receiving chronic systemic (oral, intravenous, or intramuscular)
corticosteroid therapy, or those receiving immunosuppressive therapy. Subjects in the
United States with terminal complement deficiency are excluded from participation in
this study.


6. Significant neurological disorder or history of seizure (excluding simple febrile
seizure).


7. Current chronic use of systemic antibiotics.


8. Received any investigational vaccines, drugs, or devices within 28 days before
administration of the first study vaccination.


9. Any neuroinflammatory or autoimmune condition, including, but not limited to,
transverse myelitis, uveitis, optic neuritis, and multiple sclerosis.

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now
pfizer-logoClinical Trials
Interested in learning more about clinical trials?
Discover how clinical trials work and the impact your participation could have.
Learn more ›

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Meningococcal VaccineStudy to Evaluate the Safety and Immunogenicity of Nimenrix (Registered) in Healthy Infants, Given at 3 and 12 Months of Age
NCT04819113
  1. Santiago de Compostela, A Coruna
ALL GENDERS
76 Days+
years
MULTIPLE SITES
Meningococcal VaccineA Clinical Trial to Assess the Safety, Tolerability and Immunogenicity of MenABCWY in Healthy Infants
NCT04645966
  1. Santiago de Compostela, A Coruna
  2. Badalona, Barcelona
  3. Sant Cugat del Valles, Barcelona
  4. Burgos, Castilla Y LEON
  5. Móstoles, Madrid
  6. L'Eliana, Valencia
  7. Paiporta, Valencia
  8. Almeria,
  9. Madrid,
  10. Madrid,
  11. Madrid,
  12. Madrid,
  13. Malaga,
  14. Sevilla,
  15. Sevilla,
  16. Valencia,
  17. Valencia,
  18. Valencia,
ALL GENDERS
2 Months+
years
MULTIPLE SITES
Meningococcal VaccineA Trial to Describe the Safety and Immunogenicity of MenABCWY When Administered on 2 Schedules
NCT04440176
  1. North Charleston, South Carolina
  2. Mobile, Alabama
  3. San Diego, California
  4. Orlando, Florida
  5. Atlanta, Georgia
  6. Norfolk, Nebraska
  7. Cincinnati, Ohio
  8. Cincinnati, Ohio
  9. Dayton, Ohio
  10. Fort Worth, Texas
  11. Fort Worth, Texas
  12. San Antonio, Texas
  13. Kaysville, Utah
  14. Murray, Utah
  15. Orem, Utah
  16. Roy, Utah
  17. Salt Lake City, Utah
  18. Salt Lake City, Utah
  19. South Jordan, Utah
  20. Syracuse, Utah
  21. Charlottesville, Virginia
ALL GENDERS
11 Years+
years
MULTIPLE SITES
Meningococcal VaccineMenABCWY Noninferiority Study in Healthy Participants ≥10 to <26 Years of Age
NCT04440163
  1. Cooper City, Florida
  2. Miami Lakes, Florida
  3. Oviedo, Florida
  4. Hradec Kralove,
  5. Birmingham, Alabama
  6. Birmingham, Alabama
  7. Tempe, Arizona
  8. Banning, California
  9. Madera, California
  10. Paramount, California
  11. Paramount, California
  12. Colorado Springs, Colorado
  13. Coral Gables, Florida
  14. Jupiter, Florida
  15. Lake Worth, Florida
  16. Miami Lakes, Florida
  17. Miami, Florida
  18. Miami, Florida
  19. Miami, Florida
  20. Ormond Beach, Florida
  21. Tampa, Florida
  22. Adairsville, Georgia
  23. Chamblee, Georgia
  24. Meridian, Idaho
  25. Nampa, Idaho
  26. Mishawaka, Indiana
  27. South Bend, Indiana
  28. Ankeny, Iowa
  29. West Des Moines, Iowa
  30. El Dorado, Kansas
  31. Newton, Kansas
  32. Lexington, Kentucky
  33. Baton Rouge, Louisiana
  34. Haughton, Louisiana
  35. Saint Louis, Missouri
  36. Elkhorn, Nebraska
  37. Omaha, Nebraska
  38. Binghamton, New York
  39. Salisbury, North Carolina
  40. Wilmington, North Carolina
  41. Winston-Salem, North Carolina
  42. Cleveland, Ohio
  43. Cleveland, Ohio
  44. Dayton, Ohio
  45. Fairfield, Ohio
  46. Norman, Oklahoma
  47. Yukon, Oklahoma
  48. Erie, Pennsylvania
  49. Philadelphia, Pennsylvania
  50. Charleston, South Carolina
  51. Greenville, South Carolina
  52. Bristol, Tennessee
  53. Bristol, Tennessee
  54. Chattanooga, Tennessee
  55. Kingsport, Tennessee
  56. Carrollton, Texas
  57. Plano, Texas
  58. Plano, Texas
  59. San Antonio, Texas
  60. Holladay, Utah
  61. Provo, Utah
  62. Salt Lake City, Utah
  63. Salt Lake City, Utah
  64. South Jordan, Utah
  65. Ceske Budejovice,
  66. Jindrichuv Hradec,
  67. Pardubice,
  68. Praha 6,
  69. Pribram,
  70. Aarhus N,
  71. Balatonfüred,
  72. Debrecen,
  73. Gyula,
  74. Miskolc,
  75. Székesfehérvár,
  76. Debica,
  77. Krakow,
  78. Krakow,
  79. Leczna,
  80. Siemianowice Slaskie,
  81. Trzebnica,
ALL GENDERS
10 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ?10 to <19 Years
Official Title  ICMJE A Phase 3, Randomized, Active-controlled, Observer-blinded Trial To Assess The Lot Consistency, Safety, Tolerability, And Immunogenicity Of A Meningococcal Serogroup B Bivalent Rlp2086 Vaccine In Healthy Subjects Aged >/=10 To <19 Years
Brief Summary This study is looking at a new vaccine that might prevent meningococcal disease, and will study whether healthy adolescent subjects receiving different lots of vaccine respond in a similar way. The study will also look at the safety of the new vaccine as well as how it is tolerated.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 3
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Condition  ICMJE Meningococcal Vaccine
Intervention  ICMJE
  • Biological: rLP2086
    0.5 mL dose, given at 0, 2 and 6 months (lot 1)
  • Biological: rLP2086
    0.5 mL dose, given at 0, 2 and 6 months (lot 2)
  • Biological: rLP2086
    0.5 mL dose, given at 0, 2 and 6 months (lot 3)
  • Biological: Havrix (HAV)
    0.5 mL dose or 1.0 mL dose dependent on age given at month 0 and 6.
  • Biological: Saline
    0.5 mL dose of sterile normal saline for injection.
Study Arms  ICMJE
  • Experimental: rLP2086 lot 1
    Intervention: Biological: rLP2086
  • Experimental: rLP2086 lot 2
    Intervention: Biological: rLP2086
  • Experimental: rLP2086 lot 3
    Intervention: Biological: rLP2086
  • Active Comparator: Control
    Havrix (HAV) and Saline
    Interventions:
    • Biological: Havrix (HAV)
    • Biological: Saline
Publications *

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: May 5, 2016)		3596
Original Estimated Enrollment  ICMJE
 (submitted: April 9, 2013)		3600
Actual Study Completion Date  ICMJE April 2015
Actual Primary Completion Date April 2015   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Male or female subject aged >=10 and <19 years at the time of enrollment.
  2. Healthy subject as determined by medical history, physical examination, and judgment of the investigator.
  3. Negative urine pregnancy test for all female subjects.

Exclusion Criteria:

  1. Previous vaccination with any meningococcal serogroup B vaccine.
  2. Subjects who have received prior HAV vaccination.
  3. Subjects who are scheduled to receive 1 or more doses of an HPV vaccine as part of a 3-dose series during the period between Visit 1 and 28 days after the second vaccination.
  4. Subjects receiving any allergen immunotherapy with a nonlicensed product or receiving allergen immunotherapy with a licensed product and are not on stable maintenance doses.
  5. A known or suspected defect of the immune system that would prevent an immune response to the vaccine, such as subjects with congenital or acquired defects in B cell function, those receiving chronic systemic (oral, intravenous, or intramuscular) corticosteroid therapy, or those receiving immunosuppressive therapy. Subjects in the United States with terminal complement deficiency are excluded from participation in this study.
  6. Significant neurological disorder or history of seizure (excluding simple febrile seizure).
  7. Current chronic use of systemic antibiotics.
  8. Received any investigational vaccines, drugs, or devices within 28 days before administration of the first study vaccination.
  9. Any neuroinflammatory or autoimmune condition, including, but not limited to, transverse myelitis, uveitis, optic neuritis, and multiple sclerosis.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 10 Years to 18 Years   (Child, Adult)
Accepts Healthy Volunteers  ICMJE Yes
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Canada,   Czech Republic,   Finland,   Germany,   Italy,   Poland,   United Kingdom,   United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01830855
Other Study ID Numbers  ICMJE B1971009
6108A1-3001 ( Other Identifier: Alias Study Number )
2010-023873-20 ( EudraCT Number )
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Pfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS Account Pfizer
Verification Date May 2016

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP